Granted Patent
B2
US 12,268,207 · App. 18/352,942 · Granted Apr 8, 2025
Systems and methods for extraction and cryopreservation of bone marrow
Inventors:
Erik J. Woods (Carmel, IN); Brian H. Johnstone (Fishers, IN); Dongsheng Gu (Indianapolis, IN); Aubrey Marie Sherry (Carmel, IN); Kelsey Gwen Musall (Avon, IN)
Assignee:
OSSIUM HEALTH, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods, systems, and compositions are provided for extracting bone marrow cells from bone obtained from deceased donors, for preparing the bone marrow for cryopreservation, and for obtaining desired cells from cryopreserved and fresh bone marrow. In some embodiments, the methods provide cryopreserved compositions having increased viability of bone marrow cells.
Claims (26)
1. A method for processing a biological sample comprising cells or a derivative thereof, the method comprising:
(a) generating a first volume of the biological sample comprising cells or a derivative thereof, wherein the first volume comprises a first concentration of cells or a derivative thereof;
(b) generating a second volume of the biological sample comprising cells or a derivative thereof, wherein the second volume is less than the first volume and comprises a second concentration of the cells wherein the second concentration of the cells is no more than 30% different than the first concentration of the cells;
(c) generating a freezing curve specific for the cells;
(d) cooling the first volume at a first cooling rate, wherein the first cooling rate is generated from the freezing curve which balances damage from intracellular ice formation with damage from extracellular ice formation; and
(e) cooling the second volume at a second cooling rate, wherein the first cooling rate is generated from the freezing curve;
wherein the first cooling rate and second cooling rate are about the same and wherein a post-thaw cell proliferation rate of the cells in the first volume is no more than 30% different than a post-thaw cell proliferation rate of the cells in the second volume.
2. The method of claim 1 , wherein the first volume is contained in a first container, wherein the second volume is contained in a second container, and wherein the first container and the second container are located in the same freezer during a period of the first cooling rate and the second cooling rate.
3. The method of claim 1 , wherein the second volume is less than 50% of the first volume, less than 40% of the first volume, less than 37.5% of the first volume, less than 35% of the first volume, less than 30% of the first volume, less than 20% of the first volume, less than 15% of the first volume, less than 10% of the first volume, less than 5% of the first volume, or less than 1% of the first volume.
4. The method of claim 1 , wherein a post-thaw viability rate of the cells in the first volume is no more than 30% different, no more than 25% different, no more than 20% different, no more than 15% different, no more than 13.6% different, no more than 10% different, or no more than 5% different than a post-thaw viability rate of the cells in the second volume.
5. The method of claim 1 , wherein a post-thaw cell proliferation rate of the cells in the first volume is no more than 25% different, no more than 20% different, no more than 15% different, no more than 13.6% different, no more than 10% different, or no more than 5% different than a post-thaw cell proliferation rate of the cells in the second volume.
6. The method claim 1 , wherein a post-thaw viability rate of the cells in the first volume and in the second volume are at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
7. The method of claim 1 , wherein the post-thaw cell proliferation rate of the cells is at least 1 CFU-GM/10 5 cells.
8. The method of claim 1 , wherein the first cooling rate and the second cooling rate comprise a supra-freeze rate from about −0.1° C./min to about −5° C./min and until at least ice has nucleated in a freezing medium.
9. The method of claim 8 , wherein the first cooling rate and the second cooling rate comprise a supra-freeze rate from about −2.5° C./min to about −4° C./min, from about −2.5° C./min to about −3.5° C./min, or from about −1° C./min to about −2° C./min and until at least when ice has nucleated in a freezing medium.
10. The method of claim 9 , wherein the first cooling rate and the second cooling rate comprise a supra-freeze rate of about −1° C./min.
11. The method of claim 2 , wherein step (c) occurs in one static freezer or one controlled-rate freezer, wherein the freezer is set to from about −70° C. to about −90° C.
12. The method of claim 11 , wherein the first container and the second container are disposed in the same shelf of the freezer.
13. The method of claim 11 , wherein the freezer is set at −86° C.
14. The method of claim 1 , wherein the second volume is placed directly in an insulating container.
15. The method of claim 1 , wherein the method further comprises arranging the first volume and/or the second volume inside the static freezer such that the first volume and/or the second volume does not contact a wall of the freezer.
16. The method of claim 1 , wherein the biological sample comprising cells or a derivative thereof, in the first volume and the biological sample comprising cells or a derivative thereof, in the second volume experience the same cooling rate.
17. The method of claim 16 , wherein the cells are stem cells or immune cells.
18. The method of claim 17 , wherein the stem cells comprise hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), or both.
19. The method of claim 1 , wherein the biological sample comprises one or more organs, blood, or both.
20. The method of claim 1 , further comprising a step of transferring the first volume and the second volume to a long-term storage container.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 17, 2023
From: WOODS, ERIK J.; JOHNSTONE, BRIAN H.; GU, DONGSHENG; SHERRY, AUBREY MARIE; MUSALL, KELSEY GWEN
To: OSSIUM HEALTH, INC.
Reel/Frame 065606/0255 →
Continuity (7)
Continuation
PCTUS2021055081
· Oct 14, 2021
Provisional Application
63168178
· Mar 30, 2021
Provisional Application
63130255
· Dec 23, 2020
Provisional Application
63110571
· Nov 6, 2020
Provisional Application
63091890
· Oct 14, 2020
References Cited (282)
US 4674184A
· Anderson
· 1987
[cited by applicant]
US 4710472A
· Saur et al.
· 1987
[cited by applicant]
US 5474687A
· Van Vlasselaer
· 1995
[cited by applicant]
US 5672346A
· Srour et al.
· 1997
[cited by applicant]
US 5766944A
· Ruiz
· 1998
[cited by applicant]
US 5840580A
· Terstappen et al.
· 1998
[cited by applicant]
US 5858782A
· Long et al.
· 1999
[cited by applicant]
US 6739112B1
· Marino
· 2004
[cited by applicant]
US 6900029B1
· Coulter
· 2005
[cited by examiner]
US 7470538B2
· Laughlin et al.
· 2008
[cited by applicant]
US 7547210B1
· Valen
· 2009
[cited by applicant]
US 7794705B2
· Pecora et al.
· 2010
[cited by applicant]
US 7915043B2
· Caligiuri et al.
· 2011
[cited by applicant]
US 7927785B2
· Milhem et al.
· 2011
[cited by applicant]
US 8048618B2
· Luk et al.
· 2011
[cited by applicant]
US 8088370B2
· Pecora et al.
· 2012
[cited by applicant]
US 8343485B2
· Pecora et al.
· 2013
[cited by applicant]
US 8425899B2
· Pecora et al.
· 2013
[cited by applicant]
US 8637005B2
· Pecora et al.
· 2014
[cited by applicant]
US 8709403B2
· Pecora et al.
· 2014
[cited by applicant]
US 8956862B2
· Pal
· 2015
[cited by examiner]
US 9034316B2
· Pecora et al.
· 2015
[cited by applicant]
US 9078429B2
· McGann et al.
· 2015
[cited by applicant]
US 9192695B2
· Shi
· 2015
[cited by applicant]
US 9241959B2
· Tang
· 2016
[cited by applicant]
US 9402377B2
· Flavell et al.
· 2016
[cited by applicant]
US 9409906B2
· Sauvageau et al.
· 2016
[cited by applicant]
US 9499792B2
· Chretien et al.
· 2016
[cited by applicant]
US 9504717B2
· Strober et al.
· 2016
[cited by applicant]
US 9533010B2
· Pecora et al.
· 2017
[cited by applicant]
US 9534202B2
· Pecora et al.
· 2017
[cited by applicant]
US 9561253B2
· Strober et al.
· 2017
[cited by applicant]
US 9675643B2
· Weston et al.
· 2017
[cited by applicant]
US 9675644B2
· Weston et al.
· 2017
[cited by applicant]
US 9687511B2
· Weston et al.
· 2017
[cited by applicant]
US 9808558B2
· Shi
· 2017
[cited by applicant]
US 9814803B2
· Shi
· 2017
[cited by applicant]
US 9828586B2
· Tom et al.
· 2017
[cited by applicant]
US 9945854B2
· Altman et al.
· 2018
[cited by applicant]
US 9963678B2
· Tom et al.
· 2018
[cited by applicant]
US 9974807B2
· Strober et al.
· 2018
[cited by applicant]
US 20020039786A1
· Reid et al.
· 2002
[cited by applicant]
US 20020182186A1
· Loeb
· 2002
[cited by applicant]
US 20030082158A1
· Symonds et al.
· 2003
[cited by applicant]
US 20040072347A1
· Schuler et al.
· 2004
[cited by applicant]
US 20040258670A1
· Laughlin et al.
· 2004
[cited by applicant]
US 20050233299A1
· Sawa et al.
· 2005
[cited by applicant]
US 20070036734A1
· Tahara et al.
· 2007
[cited by applicant]
US 20070224587A1
· Forsell et al.
· 2007
[cited by applicant]
US 20100178279A1
· Cunningham-Rundles et al.
· 2010
[cited by applicant]
US 20100260721A1
· McGonagie et al.
· 2010
[cited by applicant]
US 20100310535A1
· Nakamura et al.
· 2010
[cited by applicant]
US 20100310536A1
· Nakamura et al.
· 2010
[cited by applicant]
US 20120052049A1
· Woods et al.
· 2012
[cited by applicant]
US 20120276581A1
· Arav et al.
· 2012
[cited by applicant]
US 20130011376A1
· Peled et al.
· 2013
[cited by applicant]
US 20130216495A1
· Motlagh et al.
· 2013
[cited by applicant]
US 20130236433A1
· Webster
· 2013
[cited by applicant]
US 20130302293A1
· Webster
· 2013
[cited by applicant]
US 20160089401A1
· Woods et al.
· 2016
[cited by applicant]
US 20170151287A1
· Von Maltzahn et al.
· 2017
[cited by applicant]
US 20170247659A1
· Ganey et al.
· 2017
[cited by applicant]
US 20190343112A1
· Woods et al.
· 2019
[cited by applicant]
US 20190345450A1
· Radtke et al.
· 2019
[cited by applicant]
US 20200016198A1
· Jongen et al.
· 2020
[cited by applicant]
US 20210214688A1
· Johnstone et al.
· 2021
[cited by applicant]
CN 107012119
· 2017
[cited by applicant]
CN 108473949A
· 2018
[cited by applicant]
EP 3107995
· 2016
[cited by applicant]
WO WO9307824
· 1993
[cited by applicant]
WO WO03024215
· 2003
[cited by applicant]
WO WO2011069117
· 2011
[cited by applicant]
WO WO2011151452
· 2011
[cited by applicant]
WO WO2016210292
· 2016
[cited by applicant]
WO WO2017127755
· 2017
[cited by applicant]
WO WO2017216775
· 2017
[cited by applicant]
WO WO2017218948
· 2017
[cited by applicant]
WO WO2018022651
· 2018
[cited by applicant]
WO WO2019006328
· 2019
[cited by applicant]
WO WO2020047236
· 2020
[cited by applicant]
WO WO2020061180
· 2020
[cited by applicant]
WO WO2020058324
· 2020
[cited by applicant]
WO WO2020214400
· 2020
[cited by applicant]
WO WO2022020210
· 2022
[cited by applicant]
WO WO2022081909
· 2022
[cited by applicant]
AATB. Guidance Document, in Evaluation of Body Cooling at Standard D5.400. 2013. American Association of Tissue Banks: McLean, VA. p. 13.
[cited by applicant]
Ahrens et al.: Mesenchymal stem cell content of human vertebral bone marrow. Transplantation, 2004. 78(6): p. 925-929.
[cited by applicant]
Al-Mu Hem et al.: University of Cincinnati. Cryopreservation and Hyopthermal Storage of Hematopoietic Stem Cells. (2013).
[cited by applicant]
Banfi et al.: Replicative aging and gene expression in long-term cultures of human bone marrow stromal cells. Tissue Eng, 2002. 8(6): p. 901-10.
[cited by applicant]
Bara et al.: Concise review: Bone marrow-derived mesenchymal stem cells change phenotype following in vitro culture: implications for basic research and the clinic. Stem Cells, 2014. 32(7): p. 1713-23.
[cited by applicant]
Baumert et al.: Bone marrow of multiorgan donors underutilized: implications for improvement of accessibility of hematopoietic cells for transplantations. Transplantation 93(2): 165-171, 2012.
[cited by applicant]
Baxter et al.: Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells, 2004. 22(5): p. 675-82.
[cited by applicant]
Bender et al.: Impact of freeze-thaw on isolation of viable CD34+ cells from human cadaveric bone marrow. The FASEB Journal. 34(S1) (2020) Abstract.
[cited by applicant]
Bensidhoum et al.: Homing of in vitro expanded Stro-1- or Stro-1 + human mesenchymal stem cells into the NOD/SCIO mouse and their role in supporting human CD34 cell engraflment. Blood, 2004. 103(9): p. 3313-9.
[cited by applicant]
Berz et al.: Cryopreservation of hematopoietic stem cells. Am J Hematol 82(6):463-472 (2007).
[cited by applicant]
Bieback et al.: Human Alternatives to Fetal Bovine Serum for the Expansion of Mesenchymal Stromal Cells from Bone Marrow. Stem Cells. 27(9):2331-2341 (2009).
[cited by applicant]
Blashki et al.: Mesenchymal stem cells from cortical bone demonstrate increased clonal incidence, potency, and developmental capacity compared to their bone marrow-derived counterparts. J Tissue Eng, 2016. 7: p. 2041731…
[cited by applicant]
Blazar et al.: Successful donor cell engraflment in a recipient of bone marrow from a cadaveric donor. Blood 67(6):1655-1660 (1986).
[cited by applicant]
Bork et al.: DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell, 2010. 9(1): p. 54-63.
[cited by applicant]
Bruder et al.: Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem, 1997. 64(2): p. 278-94.
[cited by applicant]
Busilacchi et al.: A novel method to evaluate prethawing viability of cryopreserved CD34+ hematopoietic stem cells for autologous transplantation. The Journal of AABB. Transfusion. 60(7):1529-1535 (2020).
[cited by applicant]
Chiang et al.: Allogeneic Mesenchymal Stem Cells in Combination with Hyaluronic Acid for the Treatment of Osteoarthritis in Rabbits. PLOS ONE. 11 (2):e0149835 pp. 1-15 (2016).
[cited by applicant]
Chilima et al.: Designing the optimal manufacturing strategy for an adherent allogeneic cell therapy. BioProcess International, 2016. 14(9): p. 24-32.
[cited by applicant]
Chinnadurai et al.: Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFNgamma priming. Blood Adv, 2017. 1 (11): p. 628-643.
[cited by applicant]
Choi et al.: Dissecting Cellular Heterogeneity Using Single-Cell RNA Sequencing. Mol Cells, 2019. 42(3): p. 189-199.
[cited by applicant]
ClinicalTrials.gov Identifier: NCT01459107 (2011).
[cited by applicant]
Cox et al.: High abundance of CD271 (+) multipotential stromal cells (MSCs) in intramedullary cavities of long bones. Bone, 2012. 50(2): p. 510-7.
[cited by applicant]
CRYO2018: The 55th Annual Meeting of The Society for Cryobiology. CSIC (2018) p. 1-2.
[cited by applicant]
CRYO2019: The 56th Annual Meeting of The Society for Cryobiology. CSIC (2019) p. 1-6.
[cited by applicant]
Delloyd's Lab Tech. Standard sieves and Mesh sizes. Online publication. http://delloyd.50megs.com/moreinfo/mesh.html. pp. 2-3 (2018).
[cited by applicant]
Dennis et al.: The STRO-1 + marrow cell population is multipotential. Cells Tissues Organs, 2002. 170(2-3): p. 73-82.
[cited by applicant]
Digirolamo et al.: Propagation and senescence of human marrow stromal cells in culture: a simple colony forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol, 1999. 1…
[cited by applicant]
Dominici et al.: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 2006. 8(4): p. 315-7.
[cited by applicant]
Donnenberg et al.: Clinical implementation of a procedure to prepare bone marrow cells from cadaveric vertebral bodies. Regen Med, 2011. 6(6): p. 701-6.
[cited by applicant]
Donnenberg, Ph.D.: Working with Bone Marrow on a Grand Scale. McGowan Retreat. Mar. 2011.
[cited by applicant]
Du et al.: Rational Design of a Fluorescent Hydrogen Peroxide Probe Based on the Umbelliferone Fluorophore. Tetrahedron Letters. 49(19):3045-3048 (2008).
[cited by applicant]
Dykstra et al.: Concise Review: Fat and Furious: Harnessing the Full Potential of Adipose-Derived Stromal Vascular Fraction. Stem Cells Trans! Med, 2017. 6(4): p. 1096-1108.
[cited by applicant]
Eagle et al.: Assessment of an improved bone washing protocol for deceased donor human bone. Cell Tissue Bank. 16:83-90 (2014) DOI:10.1007/s10561-014-9443-z.
[cited by applicant]
Eckardt et al.: Comparison of engraftment and acute GVHD in patients undergoing cryopreserved or fresh allogeneic BMT. Bone Marrow Transplant, 1993. 11 (2): p. 125-31.
[cited by applicant]
Ferrari et al.: Beta regression for modeling rates and proportions. J. Applied Statistics, 2004. 31 (7): p. 799-815.
[cited by applicant]
Ferrebee et al.: The Collection, Storage and Preparation of Viable Cadaver Marrow for Intravenous Use. Blood. 14(2):140-147 (1959).
[cited by applicant]
Flood et al.: Does practice make perfect? Part 1: The relations between hospital volume and outcomes for selected diagnostic categories. Medical Care, 1984. 22(2): p. 98-114.
[cited by applicant]
Flood et al.: Does practice make perfect? Part II: The relation between volumes and other hospital characteristics. Medical Care, 1984. 22(2): p. 115-125.
[cited by applicant]
Fresenius KABI AG. 51 0(k) Summary. Bone Marrow Collection Stand. (2017) https ://www. fda .gov/med ia/1 06490/down load.
[cited by applicant]
Galipeau et al.: International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy, 2016. 18(2)…
[cited by applicant]
Galipeau et al.: Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell, 2018. 22(6): p. 824-833.
[cited by applicant]
GE Healthcare Life Sciences. Cell Separation Media Reference (2014).
[cited by applicant]
Gorantla et al.: Development and validation of a procedure to isolate viable bone marrow cells from the vertebrae of cadaveric organ donors for composite organ grafting. Cytotherapy, 2012. 14(1): p. 104-13.
[cited by applicant]
Gorantla et al.: 2007-05-R11A Procedure for preparation of bone marrow cells from cadaveric vertebral bodies. University of Pittsburgh Medical Center. pp. 1-11 (2007).
[cited by applicant]
Gronthos et al.: Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci, 2003. 116(Pt 9): p. 1827-35.
[cited by applicant]
Han et al.: Optimization of human umbilical cord mesenchymal stem cell isolation and culture methods. Cytotechnology. 65(5):819-827 (2013).
[cited by applicant]
Harrel Jr .: Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. 2nd ed. Springer Series in Statistics. 2001, NY: 582.
[cited by applicant]
Harrison et al.: Cell therapy-processing economics: small-scale microfactories as a stepping stone toward large-scale macrofactories. Regen Med, 2018. 13(2): p. 159-173.
[cited by applicant]
Heathman et al.: Characterization of human mesenchymal stem cells from multiple donors and the implications for large scale bioprocess development. Biochemical Engineering Journal, 2016. 108: p. 14-23.
[cited by applicant]
Hemacare Corporation. Isolation of Peripheral Blood Mononuclear Cells (PBMCs) Using a Density Gradient Reagent. Technical Protocol. PROT-IPBMC-V1 .1 1018 (2016).
[cited by applicant]
Hibino et al.: Comparison of Human Bone Marrow Mononuclear Cells Isolation Methods for Creating Tissue-Engineered Vascular Grafts: Novel Filter System Versus Traditional Density Centrifugation Method. Tissue Engineering…
[cited by applicant]
Hotta et al.: Long-term Nonhuman Primate Renal Allograft Survival Without Ongoing Immunosuppression in Recipients of Delayed Donor Bone Marrow Transplantation. Transplantation, 2018. 102(4): p. e128-e136.
[cited by applicant]
Hunt. Cryopreservation of Human Stem Cells for Clinical Application: A Review. Transfus Med Hemother 38(2):107-123 (2011).
[cited by applicant]
Hwang et al.: Single-cell RNA sequencing technologies and bioinformatics pipelines. Exp Mol Med, 2018. 50(8): p. 96.
[cited by applicant]
Johnstone: Edit Identification and Characterization of a Large Source of Primary Mesenchymal Stem Cells Tightly Adhered to Bone Surfaces of Human Vertebral Body Marrow Cavities. ISSCR Abstract (2020).
[cited by applicant]
Johnstone et al.: Identification and characterization of a large source of primary mesenchymal stem cells tightly adhered to bone surfaces of human vertebral body marrow cavities. Cytotherapy. (2020) 1-12.
[cited by applicant]
Johnstone et al.: Identification and characterization of a large source of primary mesenchymal stem cells tightly adhered to bone surfaces of human vertebral body marrow cavities. Reprint https://doi.org/10.1101 /2020.0…
[cited by applicant]
Johnstone et al.: Identification and characterization of a large source of primary mesenchymal stem cells tightly adhered to bone surfaces of human vertebral body marrow cavities. ScienceDirect. Cytotherapy. 22:617-628 …
[cited by applicant]
Jones et al.: Large-scale extraction and characterization of CD271 + multi potential stromal cells from trabecular bone in health and osteoarthritis: implications for bone regeneration strategies based on uncultured or …
[cited by applicant]
Jossen et al.: Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges. Appl Microbial Biotechnol, 2018. 102(9): p. 3981-3994.
[cited by applicant]
Kawai et al.: Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant, 2014. 14(7): p. 1599-611.
[cited by applicant]
Kenyon et al.: Effect of depletion of class II bright cells on the immunogenicity and stem cell content of human vertebral body bone marrow. Transplant Proc 27(6):3419 (1995).
[cited by applicant]
Knebel et al.: Allocation of scarce resources after a nuclear detonation: setting the context. Disaster Med Public Health Prep, 2011. 5 Suppl 1: p. S20-31.
[cited by applicant]
Lechanteur et al.: Large-scale clinical expansion of mesenchymal stem cells in the GMP-compliant, closed automated Quantum(R) cell expansion system: Comparison with expansion in traditional T-flasks. Stem Cell Research …
[cited by applicant]
Li et al.: Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction. Sci Rep, 2018. 8(1): p. 6816.
[cited by applicant]
Linch et al.: Bone marrow processing and cryppreservation. Journal of Clinical Pathology. 35(2):186-190 (1982.
[cited by applicant]
Lioznov et al.: Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM. Bone Marrow Transplant, 2008. 42(2): p. 121-8.
[cited by applicant]
Lipsitz et al.: A roadmap for cost-of-goods planning to guide economic production of cell therapy products. Cytotherapy, 2017. 19(12): p. 1383-1391.
[cited by applicant]
Lockhart et al.: Use of Freshly Isolated Human Adipose Stromal Cells for Clinical Applications. Aesthet Surg J, 2017. 37(suppl_3): p. S4-S8.
[cited by applicant]
Long et al.: Accumulation of CD11 b+ Gr-1 + cells in the lung, blood and bone marrow of mice infected with highly pathogenic H5N1 and H1 N1 influenza viruses. Archives of Virology. 158(6): 1305-1322 (2013).
[cited by applicant]
Mendicino et al.: MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell, 2014. 14(2): p. 141-5.
[cited by applicant]
Michalova et al.: Hematopoietic Stem Cells Survive Circulation Arrest and Reconstitute Hematopoiesis in Myeloablated Mice. Biology of Blood and Bone Marrow Transplantation. 17(9):1273-1281 (2011).
[cited by applicant]
Miller et al.: Phenotypic and Functional Equivalency of Digested Bone Marrow Mesenchymal Stem Cells to Aspirated Bone Marrow Mesenchymal Stem Cells. FASEB 33(S1) (2019).
[cited by applicant]
Miltenyi Biotec: Isolation of Mononuclear Cells from human bone marrow aspirates by density gradient centrifugation. (2008).
[cited by applicant]
Mizukami et al.: Technologies for large-scale umbilical cord-derived MSC expansion: Experimental performance and cost of g000ds analysis. Biochemical Engineering Journal, 2018. 135: p. 36-48.
[cited by applicant]
Moravcikova et al.: Proteomic Profiling of Native Unpassaged and Culture-Expanded Mesenchymal Stromal Cells (MSC). Cytometry A, 2018. 93(9): p. 894-904.
[cited by applicant]
Morgenstern et al.: Post-thaw viability of cryopreserved peripheral blood stem cells (PBSC) does not guarantee functional activity: important implications for quality assurance of stem cell transplant programmes. Br J H…
[cited by applicant]
Muraglia et al.: Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci, 2000. 113 ( Pt 7): p. 1161-6.
[cited by applicant]
Oet Jen et al.: Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry. JCI Insight. 3(23):7 e124928 (2018).
[cited by applicant]
Olsen et al.: Peak MSC-Are We There Yet? Front Med (Lausanne), 2018. 5: p. 178.
[cited by applicant]
Oseni et al.: Optimization of chondrocyte isolation and characterization for large-scale cartilage tissue engineering. Journal of Surgical Research. 181 :41-48 (2013).
[cited by applicant]
PCT/US2020/025778 International Preliminary Report on Patentability dated Oct. 28, 2021.
[cited by applicant]
PCT/US2020/025778 ISR and Written Opinion dated Sep. 16, 2020.
[cited by applicant]
PCT/US2021/055081 International Search Report and Written Opinion dated Jan. 20, 2021.
[cited by applicant]
Pennington et al.: Evaluation of a Sterling Cycle Controlled Rate Freezing Device for Simultaneous Cryopreservation of Multiple Units. Cryobiology. 91 :146-197 (2019) Abstract.
[cited by applicant]
Pereira et al.: Impact of allogeneic stem cell manufacturing decisions on cost of goods, process robustness and reimbursement. Biochemical Engineering J, 2018. 137: p. 132-151.
[cited by applicant]
Picard et al.: Cook, Cross-validation of regression models. J . Am. Stat. Assoc, 1984. 79(428):9 pages.
[cited by applicant]
Pittenger et al.: Multilineage potential of adult human mesenchymal stem cells. Science, 1999. 284(5411): p. 143-7.
[cited by applicant]
Quah et al.: Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc, 2007. 2(9): p. 2049-56.
[cited by applicant]
REDAELLI From cytogenomic to epigenomic profiles: monitoring the biologic behavior of in vitro cultured human bone marrow mesenchymal stem cells. Stem Cell Res Ther, 2012. 3(6): p. 47.
[cited by applicant]
Rybka et al.: Hematopoietic progenitor cell content of vertebral body marrow used for combined solid organ and bone marrow transplantation. Transplantation, 1995. 59(6): p. 871-4.
[cited by applicant]
Schneeberger et al.: Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg, 2013. 257(2): p. 345-51.
[cited by applicant]
Schwartz et al.: Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis, 1967. 20(8): p. 637-48.
[cited by applicant]
Sherry et al.: The Influence of Warm Ischemic Time on the Viability of Deceased Organ Donor Derived Bone Marrow. The FASEB Journal. 32(S1) Abstract (2018).
[cited by applicant]
Shu et al.: Development of a reliable low-cost controlled cooling rate instrument for the cryopreservation of hematopoietic stem cells. Cytotherapy 12(2):161-169 (2010).
[cited by applicant]
Siclari et al.: Mesenchymal proenitors residing close to the bone surface are functionally distinct from those in the central bone marrow. Bone, 2013. 53(2): p. 575-86.
[cited by applicant]
Simaria et al.: Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies. Biotechnol Bioeng, 2014. 111 (1): p. 69-83.
[cited by applicant]
Simmons et al.: Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood, 1991. 78(1): p. 55-62.
[cited by applicant]
Soderdahl et al.: Cadaveric bone marrow and spleen cells for transplantation. Bone Marrow Transplant, 1998. 21(1): p. 79-84.
[cited by applicant]
Spitzer et al.: Twenty Year Follow Up of Histocompatibility Leukocyte Antigen-Matched Kidney and Bone Marrow Co-Transplantation for Multiple Myeloma with End Stage Renal Disease: Lessons Learned. Transplantation, 103(11…
[cited by applicant]
Squillaro et al.: Clinical Trials With Mesenchymal Stem Cells: An Update. Cell Transplant, 2016. 25(5): p. 829-48.
[cited by applicant]
Stenn et al.: Dispase, a Neutral Protease From Bacillus Polymyxa, Is a Powerful Fibronectinase and Type IV Collagenase. J Invest Dermatol. 93(2):287-290 (1989).
[cited by applicant]
Stockschlader et al.: Long-term follow-up of leukaemia patients after related cryopreserved allogeneic bone marrow transplantation. Br J of Hematology. 96:382-386 (1997).
[cited by applicant]
Stockschlader et al.: Use of cryopreserved bone marrow in allogeneic bone marrow transplantation. Bone Marrow Transplant, 1995. 15(4): p. 569-72.
[cited by applicant]
Stockschlader et al.: Use of cryopreserved bone marrow in unrelated allogeneic transplantation. Bone Marrow Transplant, 1996. 17(2): p. 197-9 (Abstract).
[cited by applicant]
Suire et al.: Isolation of the stromal-vascular fraction of mouse bone marrow markedly enhances the yield of clonogenic stromal progenitors. Blood. 119(11):e86-e95 (2012).
[cited by applicant]
Sutherland The Ishage guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996. 5(3):213-26.
[cited by applicant]
Thomas et al.: Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257(11):491-496 (1957).
[cited by applicant]
Thompson et al.: Time and Temperature Dependent Ficoll Separation of Aged Whole Blood Neutrophils. The FASEB Journal. 33(S1) Abstract (2019).
[cited by applicant]
Thompson: Preparing Skeletons for Research and Teaching from Preserved Human Specimens. Thesis. pp. 1-162 (2015).
[cited by applicant]
U.S. Appl. No. 16/734,713 Final Office Action dated Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 17/013,379 Office Action dated Feb. 18, 2021.
[cited by applicant]
U.S. Appl. No. 17/013,379 Restriction Requirement dated Dec. 14, 2020.
[cited by applicant]
U.S. Appl. No. 17/013,389 Final Office Action dated Feb. 19, 2021.
[cited by applicant]
U.S. Appl. No. 17/013,389 First Action Interview dated Dec. 11, 2020.
[cited by applicant]
U.S. Appl. No. 17/013,389 Non-Final Office Action dated Apr. 7, 2021.
[cited by applicant]
U.S. Appl. No. 17/013,395 Final Office Action dated Mar. 12, 2021.
[cited by applicant]
U.S. Appl. No. 17/013,395 Final Office Action dated Sep. 27, 2021.
[cited by applicant]
U.S. Appl. No. 17/013,395 First Action Interview dated Dec. 1, 2020.
[cited by applicant]
U.S. Appl. No. 17/013,395 Non-Final Office Action dated Apr. 13, 2021.
[cited by applicant]
U.S. Appl. No. 17/013,395 Non-Final Office Action dated Jan. 13, 2023.
[cited by applicant]
U.S. Appl. No. 17/013,400 Final Office Action dated Sep. 2, 2021.
[cited by applicant]
U.S. Appl. No. 17/013,400 First Action Interview dated Dec. 28, 2020.
[cited by applicant]
U.S. Appl. No. 17/013,400 Non-Final Office Action dated Apr. 13, 2021.
[cited by applicant]
U.S. Appl. No. 17/013,407 Office Action dated Dec. 18, 2020.
[cited by applicant]
U.S. Appl. No. 17/013,407 Restriction Requirement dated Nov. 10, 2020.
[cited by applicant]
U.S. Appl. No. 17/199,376 Office Action dated Nov. 17, 2022.
[cited by applicant]
Walter et al.: Molecular and Functional Phenotypes of Human Bone Marrow-Derived Mesenchymal Stromal Cells Depend on Harvesting Techniques. International Journal of Molecular Sciences. 23.4382:1-12 (2020).
[cited by applicant]
Warwick et al.: Collagenase Clostridium histolyticum: emerging practice patterns and treatment advances. Journal of Plastic Surgery and Hand Surgery. 50(5):251-326 (2016).
[cited by applicant]
Weinstock et al.: Radiologic and nuclear events: contingency planning for hematologists/oncologists. Blood, 2008. 111 (12): p. 5440-5.
[cited by applicant]
Woods et al.: Ischemia considerations for the development of an organ and tissue donor derived bone marrow bank. Journal of Translational Medicine. 18:300 (2020) 11 pages.
[cited by applicant]
Woods et al.: Off the shelf cellular therapeutics: Factors to consider during cryopreservation and storage of human cells for clinical use. Cytotherapy, 2016. 18(6): p. 697-711.
[cited by applicant]
Woods et al.: Packaging considerations for biopreservation. Transfusion Medicine and Hemotherapy 38(2):149-156 (2011).
[cited by applicant]
Woods et al.: The learning curve and the cost of heart transplantation. Health Sery Res, 1992. 27(2): p. 219-38.
[cited by applicant]
Wright, T., Factors affecting the cost of airplanes. J Aeronautical Sci 1936. 3(2): p. 122-128.
[cited by applicant]
Vvuchter et al.: Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy, 2014. 17(2): p. 128-39.
[cited by applicant]
Yamada et al.: Overcoming memory T-cell responses for induction of delayed tolerance in nonhuman primates. Am J Transplant, 2012. 12(2): p. 330-40.
[cited by applicant]
Yescom. All Steel PEX Pipe Tube Cpvc Tubing Cutter up to 1-5/8″ Hose Ratchet Style New.|Publication [online]. https:\\www.amazon.com/Steel-Tubing-Cutter-Ratchet-Style/dp/BOOLSEHSSE. p. 1 (2014).
[cited by applicant]
Yusop et al.: Isolation and Characterisation of Mesenchymal Stem Cells from Rat Bone Marrow and the Endosteal Niche: A Comparative Study. Stem Cells Int, 2018. 2018: p. 6869128.
[cited by applicant]
First Office Action Issued for Chinese Application No. 2021800836384 dated Jan. 16, 2024 in 8 pages.
[cited by applicant]
DC Linch et al. “Bone marrow processing and cryopreservation”, Journal of Clinical Pathology vol. 35, No. 2, published Feb. 28, 1982, in 5 pages.
[cited by applicant]
Second Office Action Issued for Chinese Application No. 2021800836384 dated Aug. 19, 2024 in 4 pages.
[cited by applicant]
Extended European Search Report for Application No. 21881129.7 dated Oct. 11, 2024 in 9 pages.
[cited by applicant]
Fuller et al., “Applications and Optimization of Cryopreservation Technologies to Cellular Therapeutics,” Cell and Gene Therapy Insights, vol. 3, No. 5, dated Jun. 6, 2017, pp. 359-378.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/055081 dated Jan. 20, 2022 in 13 pages.
[cited by applicant]
Cited By (1)